

IFW

Patent Application
Attorney Docket No. PC25698A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 14th day of May, 2004.

By

Kelly A. Smith

(Signature of person mailing)

Kelly A. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Laura C. Blumberg, et al. :

APPLICATION NO.: 10/783,251 : Examiner:

FILING DATE: September 20, 2004 : Group Art Unit:

TITLE: NOVEL FUSED HETEROAROMATIC :
COMPOUNDS AS TRANSFORMING
GROWTH FACTOR (TGF) INHIBITORS

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 (b)

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: 5/14/04


Respectfully submitted,

Christine S. Lee

Christine S. Lee
Attorney for Applicant(s)
Reg. No. 42,788

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686-2144

#71714 v1 - PC25698A INFORMATION DISCLOSURE STATEMENT




INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC25698A	SERIAL NO. 10/783,251
	APPLICANT Laura C. Blumberg, et al.	
	FILING DATE February 20, 2004	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	6	6	9	6	4	6	4	2/24/04	McClure, et al.	514	303	
	US	6	6	6	4	3	9	5	12/16/03	Letavic, et al.	544	405	
	US	3	5	3	8	2	1	4	11/3/70	Polli, et al.	424	19	
	US	4	0	6	0	5	9	8	11/29/77	Groppenbacher, et al	424	33	
	US	4	1	7	3	6	2	6	11/6/79	Demski, et al.	424	19	
	US	3	1	1	9	7	4	2	1/28/64	Heimlich, et al.	167	82	
	US	3	4	9	2	3	9	7	1/27/70	Peters, et al.	424	20	
	US	5	6	5	6	6	4	4	8/12/97	Adams, et al.	514	341	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
									Mo/day/yr				YES	NO
	WO	0	2	4	0	4	7	6	5/23/02	International				
	WO	9	6	3	0	3	4	7	10/3/96	International				
	WO	0	3	0	0	6	8	2	1/3/03	International				
	WO	9	8	5	2	9	3	7	11/26/98	International				
	WO	9	8	5	2	9	4	1	11/26/98	International				
	WO	0	0	3	1	0	6	3	6/2/00	International				
	WO	0	2	6	2	7	8	7	8/15/02	International				
	WO	0	2	6	2	7	9	4	8/15/02	International				
	WO	0	2	6	6	4	6	2	8/29/02	International				
	WO	0	2	5	5	0	7	7	7/18/02	International				
	WO	0	2	4	0	4	6	8	5/23/02	International				
	WO	0	2	1	6	3	5	9	2/28/02	International				
	WO	0	1	7	2	7	3	7	10/4/01	International				
	WO	0	1	6	2	7	5	6	8/30/01	International				
	WO	0	0	6	1	5	7	6	10/19/00	International				
	WO	0	3	8	7	3	0	4	10/23/03	International				



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC25698A				SERIAL NO. 10/783,251									
										APPLICANT Laura C. Blumberg, et al.													
										FILING DATE February 20, 2004										GROUP			
	WO	0	4	1	3	1	3	5	2/12/04	International													
	EP	0	2	5	7	8	9	7	3/2/88	Europe													
	WO	0	2	7	2	5	7	6	9/19/02	International													
	WO	0	4	2	1	9	8	9	3/18/04	International													
	WO	0	4	1	3	1	3	8	2/12/04	International													
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																							
			Dombroski, et al., U.S. Patent Publication No. 2003/0092749, May 15, 2003																				
			Laping, et al., "Inhibition of Transforming Growth Factor (TGF)- β 1-Induced Extracellular Matrix with a Novel Inhibitor of the TGF- β Type I Receptor Kinase Activity: SB-431542", Mol. Pharmacol., 62:58-64, 2002																				
			Moran, et al., "Synthesis of (Pyridinyl)-1,2,4-triazolo[4,3- α]pyridines" J. Heterocycl. Chem., 23:1071-1077, 1986																				
			Singh, et al., "Successful Shap-Based Virtual Screening: The Discovery of a Potent Inhibitor of the Type I TGF β Receptor Kinase (T β RI)", Bioorganic & Medicinal Chemistry Letters, 13, pp. 4355-4359 (2003)																				
EXAMINER																							
DATE CONSIDERED																							
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																							

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE